Infamous Alzheimer APOE gene

Oct 7, 2015 | | Say something

Infamous Alzheimer APOE gene ;

95% of the time, a combination of genetics is needed badly environment and unhealthy life style to trigger Alzheimer’s disease. However, a gene called apolipoprotein E (APOE) can make a big difference. Learn more.

Most people with Alzheimer’s have late-onset Alzheimer , in which the symptoms become evident in the mid-60s and later. The causes of late-onset Alzheimer’s disease are not yet known exactly, but is likely to include a combination of genetic, environmental and lifestyle that affect a person’s risk of developing the disease factors.

Researchers have not found a specific gene that directly causes late-onset form of the disease. However, a genetic risk factor that has a form of apolipoprotein E (APOE) gene on chromosome 19 which increases the risk of a person.


APOE comes in several different forms, or alleles

  • ε2 APOE is relatively rare and can provide some protection against the disease. If Alzheimer’s disease in a person with this allele occurs, usually it develops later in life than it would be in someone with the gene APOE ε4.
  • APOE ε3 , the most common allele, is believed to play a neutral role in the disease nor decrease or increase risk.
  • APOE ε4 increases the risk for Alzheimer’s disease and is also associated with an earlier age of onset of the disease. A person who has zero, one or two APOE e4 alleles. APOE e4 allele have more increases the risk of developing Alzheimer’s disease.
Related Post:   TDP-43 amplifies 10 times Alzheimer

ε4 APOE gene is called a risk factor because it increases the risk of developing the disease a person. However, the legacy of an APOE ε4 allele definitely does not mean a person developing Alzheimer’s disease. Some people with APOE ε4 allele never get the disease, and other people who develop Alzheimer’s disease have no APOE e4 alleles.

A method called whole genome sequencing determined the entire DNA sequence of the genome of an individual at one time.

Using a relatively new approach called around the association study (GWAS) , genome researchers have identified a number of ROIs in the genome (set of a whole organism DNA, including all its genes) that may increase a person’s risk for late-onset Alzheimer’s disease in varying degrees. 2015, had confirmed 33 regions of interest in the genome of Alzheimer.

Genetic testing

A blood test can determine which APOE alleles a person has, but the results can not predict who will or will not develop Alzheimer’s disease. It is unlikely that genetic testing ever be able to predict the disease with 100 percent accuracy, researchers believe, because too many other factors can influence its development and progression.

Currently, APOE testing is used in research settings to identify study participants who may be at increased risk of developing Alzheimer’s disease. This knowledge helps scientists look for changes in the brain in the first participants and compare the effectiveness of treatments for people with different profiles of APOE. Most researchers believe that APOE testing is useful to study the risk of Alzheimer’s disease in large groups of people, but not to determine the risk of a particular person.

Related Post:   Older patients should move closer to home

Genetic testing is used by researchers conducting Clinical trials and by doctors to help diagnose the disease early onset Alzheimer’s. However, genetic testing is not recommended otherwise.

Genetics Research efforts ongoing Alzheimer Mayor

National Institute on Aging supports several major genetic research programs.

  • The Sequencing Project Alzheimer’s disease (ADSP) is an innovative collaboration between the NIA and the National Institute for Human Genome Research, that they are part of the NIH. The first phase of the project determines the order of the 3 billion letters in the individual genomes of 580 participants. It also generated the sequencing data for whole exome 11,000 additional volunteers.
  • The Genetics Consortium Alzheimer’s disease is a collaborative effort to collect and analyze genetic data from thousands of families around the world to identify genes associated with an increased risk of late onset
  • Alzheimer.

  • The Study of Genetic Disease late-onset Alzheimer is to collect and analyze genetic information and another 1,500 or more families in the United States with two or more members they have late onset of
  • Alzheimer.

  • The Draft International Genomics Alzheimer (GIFS) consists of four consortia in the United States and Europe have been working together since 2011 in studies of genome-wide association (GWAS) with thousands of DNA samples and shared datasets. In a study of more than 74,000 individuals, GIFS recently reported the identification of 19 new regions of interest that are associated with the disease.
  • The Genetics site data storage Alzheimer’s disease (NIAGADS) is a national data repository genetics that gives researchers access to data for the study of the genetics of late-onset Alzheimer’s disease.
  • The National Repository cell for Alzheimer’s disease (NCRAD) is a national resource that helps researchers find genes that increase the risk of Alzheimer’s disease, providing biological samples and data.

Volunteers are essential for genetic research of Alzheimer’s disease. The genetic information that researchers can collect and analyze individuals and families in both healthy volunteers and those who may be at risk -the more clues that will search for new genes risk factors.

For more information on genetic studies of Alzheimer’s disease, contact the toll free number 1-800-526-2839 NCRAD or visit.

to learn more about volunteering for clinical trials and studies of Alzheimer’s disease, visit

This article was originally published on alzheimersweekly, Read the original article here

You may also like:

Posted in: Alzheimer's & Dementia, Genes, Understanding Dementia

Leave a Reply

Your email address will not be published. Required fields are marked *

==[Click 2x to Close X]==
Most Popular Today!